Literature DB >> 22576286

Topical Ankaferd hemostat application for the management of oral cavity bleedings in children with hemorrhagic diathesis.

Goksel Leblebisatan1, Ali Bay, Suleyman C Karakus, Murat Kekilli, Ibrahim C Haznedaroglu.   

Abstract

Ankaferd blood stopper (ABS) is a hemostatic agent used topically for controlling bleedings of skin or mucosal surfaces in Turkey. It is currently topically used in bleedings of body injuries, traumas, and minor or major surgical interventions. Here we have evaluated 12 pediatric patients with hemorrhagic diathesis on whom Ankaferd was used for oral bleedings. Topical Ankaferd was administered for hemorrhages of oral cavity during 15 bleeding attacks. ABS administrations successfully stopped the bleedings, except for one patient with oral hemorrhage who did not respond to ABS application. Ankaferd is effective for oral bleedings of children with bleeding diathesis especially when other measures have failed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576286     DOI: 10.1097/MBC.0b013e32834fa837

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  Successful Treatment of Refractory Gastrointestinal Bleeding by Systemic (Oral) Ankaferd Blood Stopper in a Patient with Glanzmann Thrombasthenia.

Authors:  Sibel Kabukçu Hacıoğlu; Mehmet Hilmi Doğu; İsmail Sarı; Ali Keskin
Journal:  Balkan Med J       Date:  2015-04-01       Impact factor: 2.021

2.  Beneficial effects of Ankaferd Blood Stopper on dermal wound healing: an experimental study.

Authors:  Cagri Akalin; Serdar Kuru; Aziz Mutlu Barlas; Kemal Kismet; Bugra Kaptanoglu; Aydin Demir; Hesna Muzeyyen Astarci; Huseyin Ustun; Ertugrul Ertas
Journal:  Int Wound J       Date:  2012-09-03       Impact factor: 3.315

3.  Assessment of the efficacy of Ankaferd blood stopper on the prevention of postoperative pericardial adhesions.

Authors:  Yunus Nazli; Necmettin Colak; Mehmet Fatih Alpay; Hacer Haltas; Omer Nuri Aksoy; Ismail Olgun Akkaya; Omer Cakir
Journal:  Cardiovasc J Afr       Date:  2014-03-14       Impact factor: 1.167

4.  Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level.

Authors:  Emre Huri; Engin Dogantekin; Murvet Hayran; Umit Yavuz Malkan; Mine Ergun; Aysegul Firat; Yavuz Beyazit; Huseyin Ustun; Murat Kekilli; Mumtaz Dadali; Muzeyyen Astarci; Ibrahim C Haznedaroglu
Journal:  Springerplus       Date:  2016-11-08

Review 5.  Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.

Authors:  Cem Simsek; Sebnem Selek; Meltem Koca; Ibrahim Celal Haznedaroglu
Journal:  SAGE Open Med       Date:  2017-07-27

6.  Effects of Ankaferd BloodStopper on bone healing in an ovariectomized osteoporotic rat model.

Authors:  Şeref Ezirganli; Hakki Oğuz Kazancioğlu; Ahmet Hüseyin Acar; Hakan Özdemir; Emre Kuzu; Deniz Şahin İnan
Journal:  Exp Ther Med       Date:  2017-03-01       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.